MetaCap

Context Therapeutics (CNTX) vs NewcelX (NCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NewcelX (NCEL) has outperformed Context Therapeutics (CNTX) over the past year, losing 22.3% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -99.7% for NCEL. Context Therapeutics is the larger company by market cap ($14.7 million vs $14.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTX-85.32%NCEL-22.32%
+223%+61%-100%
Nov 21, 20251 yearNov 20, 2026
CNTX-96.73%NCEL-99.68%
+16%-45%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTX versus NCEL key metrics
MetricCNTXNCEL
Share price$0.16$2.54
Market cap$14.70M$14.67M
1-day change-5.10%-5.58%
YTD return-89.12%+33.68%
1-year return-85.32%-22.32%
5-year return-96.86%-99.65%
P/E ratio (TTM)—4.88
EPS (TTM)$-0.46$0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-36.12M$-8.30M
52-week high$3.62$5.12
52-week low$0.153$1.83
Distance from 52-week high-95.58%-50.39%
Analyst consensusnonenone
Avg. price target upside+2418.75%+805.51%
Average volume1.42M13.34K
Shares outstanding91.88M5.78M
Employees159
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NCEL has outperformed CNTX by 63.0 percentage points over the past year.

About Context Therapeutics

CNTX stock →

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About NewcelX

NCEL stock →

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

CNTX vs NCEL FAQ

Which is bigger, Context Therapeutics or NewcelX?

Context Therapeutics (CNTX) is larger, with a market capitalization of $14.70M compared with $14.67M for NewcelX (NCEL).

Which stock has performed better over the past year, CNTX or NCEL?

NCEL returned -22.32% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.

Are Context Therapeutics and NewcelX in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons